Kalaris Therapeutics filings document formal disclosures for a Nasdaq-listed clinical-stage biopharmaceutical company developing retinal-disease therapeutics. The record includes 8-K reports on operating and financial results, Regulation FD clinical presentations for TH103, material-event disclosures, capital-structure matters, and executive officer changes.
Proxy materials describe annual meeting and shareholder voting matters, while security disclosures identify Kalaris common stock under the KLRS ticker. Clinical disclosures focus on TH103 safety, tolerability, pharmacokinetics, early efficacy information, manufacturing updates, and the company's retinal-disease development plans.
Kalaris Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 3, 2026. Stockholders elected directors Napoleone Ferrara, M.D., David Hallal, and Leone Patterson, with each receiving more than 15.6 million votes in favor and roughly 0.5–0.7 million votes withheld.
Stockholders cast an advisory vote on executive compensation and a separate advisory vote on how often to hold future executive compensation votes. A large majority, with 16,336,117 votes, supported holding this advisory vote every year. After reviewing these results, the Board of Directors plans to conduct future advisory votes on named executive officer pay annually. Another proposal received 19,771,260 votes for, 1,583 against, and 601 abstentions.
Kalaris Therapeutics’ major shareholder group tied to Samsara BioCapital has updated its Schedule 13D, reporting a controlling stake in the company’s common stock. Dr. Srinivas Akkaraju is deemed to beneficially own 12,900,583 shares, representing 54.2% of the 23,792,278 shares outstanding as of May 5, 2026.
The filing details that on May 20, 2026, Samsara Opportunity Fund bought 244,300 shares from Samsara BioCapital, L.P. in a private sale at $4.83 per share, for a total of $1,179,969, funded with partner capital. Samsara LP also made a pro rata in-kind distribution of 66,906 shares, reallocating holdings among affiliated entities.
Kalaris Therapeutics, Inc. reported an insider group transaction where an affiliated investment vehicle, Samsara Opportunity Fund, L.P., bought 244,300 shares of common stock at $4.83 per share in a privately negotiated deal with Samsara BioCapital, L.P.
The filing also records several non-market, pro rata in-kind distributions among related Samsara entities, reallocating a total of 86,314 shares of Kalaris common stock internally. Following the purchase, Samsara Opportunity Fund, L.P. holds 2,224,147 Kalaris shares indirectly associated with director and ten percent owner Dr. Srinivas Akkaraju.
Kalaris Therapeutics reported a net loss of $10.9 million for the quarter ended March 31, 2026, slightly wider than the $10.2 million loss a year earlier. Operating expenses rose to $11.8 million, driven mainly by higher research and development spending of $7.6 million as the company advances its lead retinal drug candidate TH103.
General and administrative costs were stable at $4.3 million. Other income of $1.0 million partially offset the operating loss. Kalaris ended the quarter with $104.9 million in cash, cash equivalents and marketable securities and total assets of $109.8 million, against total liabilities of $41.2 million, including a $32.1 million royalty obligation to its majority stockholder Samsara BioCapital.
Net cash used in operating activities was $11.6 million, and the company shifted $70.4 million into U.S. Treasury marketable securities. Management believes existing liquidity will fund operating and capital needs for at least 12 months from the financial statement issuance date while it continues developing TH103 for retinal diseases.
Kalaris Therapeutics reported first‑quarter 2026 results and highlighted progress in its retinal disease program TH103. As of March 31, 2026, the company held $104.9 million in cash, cash equivalents and marketable securities and expects this to fund operations into the fourth quarter of 2027 and through key clinical milestones.
Research and development expenses rose to $7.6 million from $6.0 million a year earlier as additional clinical sites were opened and patients enrolled. General and administrative expenses were stable at $4.3 million. Net loss was $10.9 million, compared with $10.2 million in the prior‑year quarter, with no revenue reported.
The company has begun patient screening in its Phase 1b/2 trial of TH103 for neovascular age‑related macular degeneration and has manufactured new clinical material for upcoming dosing. It anticipates preliminary Phase 1b/2 data in the first half of 2027 and continues to plan Phase 3 trials targeted for initiation by year‑end 2027.
Kalaris Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 3, 2026 at 11:30 a.m. Eastern. Proposals include electing three Class III directors, an advisory say-on-pay vote, an advisory vote on say-on-pay frequency, and ratifying Deloitte & Touche LLP as auditor.
The record date is April 6, 2026, with about 11,496,146 common shares outstanding for quorum. Kalaris is classified as a “smaller reporting company” and a “controlled company,” allowing scaled disclosures and some exemptions from Nasdaq independence requirements. The meeting will be held exclusively online via www.proxydocs.com/KLRS.
Kalaris Therapeutics, Inc. registered up to $100,000,000 of common stock for sale through an at-the-market program with TD Securities (USA) LLC (TD Cowen). The prospectus permits sales from time to time at market prices, including negotiated block trades or sales on The Nasdaq Global Market.
The prospectus states 22,902,418 shares were outstanding as of December 31, 2025 and discloses an illustrative assumed offering price of $5.79 per share used to show dilution. Compensation to TD Cowen is up to 3.0% of gross proceeds and the company may sell shares to TD Cowen as principal. Net proceeds are intended for general corporate purposes including R&D, clinical development, working capital and potential acquisitions.